A Pilot Open-Label Study to Investigate the Safety and Anti-inflammatory Effects of VX-765, an Orally Administered Interleukin-1β Converting Enzyme Inhibitor, in Patients with Muckle-Wells Syndrome

Mise à jour : Il y a 5 ans
Référence : EUCTR2004-000283-27